Clinical trials: Inherited Erythromelalgia
Inherited Erythromelalgia
Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia
The purpose of this study is to evaluate the efficacy and safety of single doses of PF-05089771 against placebo in treatment of pain in patients with primary, inherited erythromelalgia.
- Trial name
- IEM (NCT01769274)
- Testing
- PF-05089771
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Primary Inherited Erythromelalgia
A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia
The primary objective of the study is to investigate the efficacy of repeat oral dosing of BIIB074 on paroxysmal pain in participants with Primary Inherited Erythromelalgia (EM).
- Trial name
- NCT02917187
- Testing
- BIIB074
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Biogen
Primary Erythromelalgia, Inherited Erythromelalgia
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM).
- Trial name
- NCT01486446
- Testing
- XPF-002
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Primary Erythromelalgia, Inherited Erythromelalgia
Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM).
- Trial name
- NCT01090622
- Testing
- XPF-001
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Xenon Pharmaceuticals Inc.